Compare Novo Nordisk A/S (NVO) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Wells Fargo & Co — how do they compare? Novo Nordisk A/S trades at $44.88 (market cap $200.69B), while Wells Fargo & Co trades at $90.17 (market cap $265.99B). The key difference: Wells Fargo & Co is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | WFC | |
|---|---|---|
Market Cap | $200.69B | $265.99B |
Sector | Health | Financials |
52-Week High | $63.98 | $96.40 |
52-Week Low | $35.29 | $73.42 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Wells Fargo (WFC) trades at $87.98, down 2.21% on the day, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 12.78, net income margin of 25.97%, and recent Q2 2026 earnings beat. CEO Charlie Scharf emphasized strategic initiatives at the 2026 healthcare conference (CNBC, 2026-09-09), while the bank expands its wealth management division (Bloomberg via Yahoo Finance, 2026-08-28).
Outlook is cautiously positive with a consensus price target of $97.64, though risks include volatile cash flows and regulatory scrutiny. Investment opportunity lies in sustained profitability improvements and ROTCE targets, but investors face headwinds from interest rate sensitivity and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
